AVE(SH:688067) Shang Hai Zheng Quan Bao·2025-10-21 19:52Core Viewpoint - The company, Awei Technology Co., Ltd., has announced a voluntary disclosure regarding its investment in Hunan Luying Technology Co., Ltd., indicating a strategic move to enhance its business capabilities and market position in the medical imaging sector [1][14]. Investment Overview - The investment target is Hunan Luying Technology Co., Ltd., with an investment amount of RMB 10 million, resulting in a 9.0744% equity stake in Luying Technology after the capital increase [1][3]. - The total investment for this round is RMB 30 million, with Awei contributing RMB 10 million, and the investment is approved within the general manager's authority, not requiring board or shareholder approval [3][4]. - The investment does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1][5]. Target Company Information - Hunan Luying Technology Co., Ltd. is focused on developing high-resolution single-photon emission computed tomography (SPECT) and its core components, aiming to provide advanced molecular imaging diagnostic solutions [5][14]. - The company was established less than a year ago and currently does not have sales revenue or profitability, with its core product still under development [5][14]. Strategic Importance - The investment aligns with the company's strategic development plan, aiming to strengthen its core business while seeking new growth opportunities in the rapidly growing medical imaging and radiation therapy equipment market [14][15]. - The SPECT/CT technology is recognized for its clinical value in early cancer diagnosis and has significant market potential, supported by government policies promoting the domestic development of nuclear medicine equipment [14][15]. Financial Impact - The investment is expected to enhance the company's overall competitiveness and is made using the company's own funds, ensuring no adverse impact on its financial status or operations [15]. - The long-term benefits of the investment will depend on Luying Technology's future operational performance [15].